C.R. Bard said it has closed on the acquisition of California-based SenoRx and folded the company’s operations into its peripheral vascular division. The acquisition, which was initially ...

In 2016,C.R. Bard's sales increased 9% to$3.7 billion and its adjusted net income increased 12% to$777.3 million. In January, management told investors to expect sales to grow between 4% and 5% ...

C.R. Bard BCR ended the day up $6.32, or 8.3%, to close at $82.68. The company reported late Wednesday that net income was $87.6 million, or 82 cents a share, compared with $90.4 million, or 83 ...

C.R. Bard Inc. was ordered to pay $35 million in punitive damages to a woman who blamed her injuries on the company’s vaginal mesh inserts in the medical supplier’s first case over the ...

C.R. Bard pays a quarterly dividend of $0.21 per share, for a annual dividend yield of merely 0.7%. Some Historical Perspective Over the past decade, shares of C.R. Bard have nearly tripled.

C.R. Bard, Inc. faces more than 13,000 lawsuits in the federal MDL, which is situated in the Southern District of Ohio. The company also faces more than 12,000 lawsuits filed in state court actions.

During the past fiscal year, BARD (C.R.) INC increased its bottom line by earning $5.34 versus $4.60 in the prior year. This year, the market expects an improvement in earnings ($6.38 versus $5.34).

Looking at the universe of stocks we cover at Dividend Channel, on 4/26/12, C.R. Bard, Inc. (NYSE: BCR) will trade ex-dividend, for its quarterly dividend of $0.19, payable on 5/11/12. As a ...

C.R. Bard pre-loads its own catheters into the handheld stylet used with the device. AngioDynamics wants the court to force C.R. Bard to stop this practice of pre-loading its catheters into its ...

Investors in C.R. Bard, Inc. (NYSE: BCR) saw new options begin trading today, for the July 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

C.R. Bard's largest product group, oncology, saw $241.9 million in sales for the quarter, an 8 percent increase. Surgical specialties saw an 11 percent change year over year, rising to $151.4 ...

C.R. Bard says acquiring Medafor gives it the opportunity to expand in the global market for surgical hemostats, which is over $1.4 billion. C.R. Bard expects the transaction to add approximately ...